Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking a pediatric indication for active immunization against invasive pneumococcal disease (IPD) and otitis media caused by serotypes included in the vaccine.

More: continued here

This entry was posted on Sunday, June 1st, 2008 at 8:06 pm and is filed under Infectious Diseases / Bacteria / Viruses. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.